Fumisuke Matsuo - Academia.edu (original) (raw)
Papers by Fumisuke Matsuo
John Wiley & Sons, Ltd eBooks, Nov 17, 2015
Neurology, Sep 1, 1992
Article abstract-An atypical form of herpes simplex encephalitis produced by HSV-1 documented in ... more Article abstract-An atypical form of herpes simplex encephalitis produced by HSV-1 documented in the present article demonstrates that (1) prominent EEG abnormality may correlate with subtle increase in signal intensity on MRI; (2) the disease may start with prominent involvement of the cingulate gyri; and (3) viral infection of the brainstem may cause early onset of severe neurologic dysfunction and coma.
Archives of neurology, Jul 1, 1979
Page 1. Safety Precautions With Spongiform Encephalopathy To the Editor.\p=m-\Thearticle of Cook ... more Page 1. Safety Precautions With Spongiform Encephalopathy To the Editor.\p=m-\Thearticle of Cook and Austin in the Archives (35:697\x=req-\ 698,1978) contains disturbing implica-tions, which may have far-reaching results that were obviously not the intention of the authors. ...
Blackwell Science, Inc. eBooks, Jan 14, 2008
Neurology, 2016
OBJECTIVE: Report a unique case of immunotherapy and anti-epileptic drug (AED)-resistant Glutamic... more OBJECTIVE: Report a unique case of immunotherapy and anti-epileptic drug (AED)-resistant Glutamic acid decarboxylase 65 (GAD65)-associated autoimmune epilepsy demonstrating improvement with exogenous testosterone replacement. BACKGROUND: Treatment response in autoimmune epilepsy is variable, often dependent on the specific neuronal antibody involved, with GAD65-associated epilepsy amongst the most challenging to treat. There have been reports of improvement in seizure frequency in non-autoimmune epilepsy following administration of testosterone; however, an association between sex steroids and autoimmune epilepsy has not been reported previously. DESIGN/METHODS: Case Report RESULTS: A 47-year-old Caucasian man with treatment refractory GAD65-associated autoimmune epilepsy (CSF and serum GAD65 titer >250 IU/mL) and primary hypogonadism was admitted for long-term video EEG monitoring to objectify the patient9s observation that the testosterone replacement prescribed by his primary ...
American Journal of EEG Technology, 1986
ABSTRACT.REM sleep can be easily identified in standard EEG montages by analysis of eye movements... more ABSTRACT.REM sleep can be easily identified in standard EEG montages by analysis of eye movements in sleep, and the method of visual analysis was described. The patient should be asked upon arousal whether or not dreaming has occurred. Identification of REM sleep is important, because it may indicate significant abnormality of the wake-sleep cycle. Overnight sleep deprivation alone may be sufficient to cause shortening of the REM latency. Common clinical features that were associated with REM sleep in standard EEGs, were reviewed. The hospital environment is particularly likely to interfere with the patients' wake-sleep cycle.
Electroencephalography and Clinical Neurophysiology, 1995
The Western journal of medicine, 1990
Journal of the Iowa Medical Society, 1976
Neurology, 1985
ABSTRACT We conducted a pilot study of fluzinamide in 15 adults with refractory partial seizures.... more ABSTRACT We conducted a pilot study of fluzinamide in 15 adults with refractory partial seizures. After a baseline period, fluzinamide was added to the existing regimen of phenytoin and carbamazepine and increased to maximum tolerated dose. Common side effects included dizziness, diplopia, ataxia, headache, nausea, and rash, resulting in patient withdrawal in six cases. Seizures became less frequent in four of the nine patients who completed the 8-week trial.
Archives of Neurology, 1982
The Treatment of Epilepsy
Neurology, Nov 1, 1993
We evaluated the efficacy and safety of lamotrigine (300 and 500 mg/day) as add-on therapy in a m... more We evaluated the efficacy and safety of lamotrigine (300 and 500 mg/day) as add-on therapy in a multicenter, randomized, double-blind, parallel-group, placebo-controlled study of 216 patients with refractory partial seizures. During 6 months of treatment, median seizure frequency decreased by 8% with placebo, 20% with 300 mg lamotrigine, and 36% with 500 mg lamotrigine. Seizure frequency decreased by ≥50% in one-third of the 500-mg group and one-fifth of the 300-mg group. Reductions in seizure frequency and seizure days were statistically significant, compared with placebo, for the 500-mg group but not the 300-mg group. Most adverse events were minor and resolved over time. Nine percent of patients on lamotrigine withdrew because of adverse experiences. Lamotrigine plasma concentrations appeared to be a linear function of dose, and the drug did not affect plasma concentrations of concomitant antiepileptic drugs. Lamotrigine was safe, effective, and well tolerated as add-on therapy for refractory partial seizures.
The New England Journal of Medicine, Jun 25, 1998
Background Acute repetitive seizures are readily recognizable episodes involving increased seizur... more Background Acute repetitive seizures are readily recognizable episodes involving increased seizure frequency. Urgent treatment is often required. Rectal diazepam gel is a promising therapy. Methods We conducted a randomized, doubleblind, parallel-group, placebo-controlled study of home-based treatment for acute repetitive seizures. Patients were randomly assigned to receive either rectal diazepam gel, at doses ranging from 0.2 to 0.5 mg per kilogram of body weight on the basis of age, or placebo. Children received one dose at the onset of acute repetitive seizures and a second dose four hours later. Adults received three doses-one dose at onset, and two more doses 4 and 12 hours after onset. Treatment was administered by a care giver, such as a parent, who had received special training. The number of seizures after the first dose was counted for 12 hours in children and for 24 hours in adults.
Epilepsy & Behavior, Feb 1, 2004
This open-label, 6-year continuation study of several short-term clinical trials was conducted to... more This open-label, 6-year continuation study of several short-term clinical trials was conducted to assess the long-term tolerability and efficacy of lamotrigine when used as adjunctive therapy or monotherapy for partial seizures in adult patients (P 16 years) with epilepsy. Study visits occurred every 24 weeks throughout the treatment period. Of the 527 patients enrolled in the long-term continuation study, 508 were exposed to lamotrigine for at least 6 months (including their exposure in the primary clinical study), and 248 were exposed to lamotrigine for at least 5 years. Of the 527 patients, 75 received initial lamotrigine exposure during this study. Investigators judged that overall clinical status at the end of the study or at time of discontinuation (whichever occurred first) was improved moderately or markedly relative to prelamotrigine clinical status for 36% of patients. The most common treatment-emergent adverse events (regardless of suspected cause) were dizziness, diplopia, and headache. The only serious treatment-emergent adverse event occurring at a frequency exceeding 2% was accidental injury (2.7% of patients). Adverse events prompted 28 patients to discontinue from the study. The most common adverse events leading to discontinuation were dizziness (1.3%), headache (0.8%), rash (0.8%), and somnolence (0.6%). All adverse events resolved without sequelae. Lamotrigine administered as monotherapy or adjunctive therapy during a 6-year open-label continuation study was associated with a low incidence of adverse events in adult patients with epilepsy.
Electroencephalography and Clinical Neurophysiology, May 1, 1975
Electroencephalography and Clinical Neurophysiology, Nov 27, 1976
Neurosurgery, Feb 1, 1986
Neurosurgery, Feb 1, 1986
This case report describes a 29-year-old man with subarachnoid hemorrhage due to an anterior spin... more This case report describes a 29-year-old man with subarachnoid hemorrhage due to an anterior spinal artery aneurysm. Surgical obliteration of the aneurysm was successful. This is the sixth reported case of an isolated symptomatic aneurysm of a spinal artery.
Epilepsia, Sep 1, 1996
This study was undertaken to evaluate the dose tolerability and safety of a chronic ascending twi... more This study was undertaken to evaluate the dose tolerability and safety of a chronic ascending twice-daily (b.i.d.) dosage regimen of G700 mg/day larnotrigine (LTG) and to include determination of the LTG pharmacokinetic profile at doses 2500 mg/day in patients receiving concomitant enzyme-inducing antiepileptic drugs (AEDs). Methods: Twelve adult male epileptic patients treated with enzyme-inducing AEDs received S700 mg/day (b.i.d.) oral LTG (n = 8) or placebo (controls, n = 4). For 3 weeks, as outpatients they had their LTG dosage increased from 100 to 400 mg/day. Then, in a clinical research study unit, patients received regimens of 500, 600, and 700 mg/day for 1 week each. Controls received matching placebo in the same sequence. At study end, dosages were tapered in 2 weeks. Follow-up evaluations were made 7 days later. Results: Five LTG patients tolerated 700 mg/day for 1 week. LTG was reduced to 600 mglday in a patient with mild diplopia and to 500 mg/day in a patient with mild oscillopsia and diplopia. One patient discontinued 300mg/day therapy with a moderately intense diffuse papular skin rash, attributed to LTG. Headache, drowsiness, faintness, and diplopia, the common adverse events (AEs), were mild to moderate in intensity and occurred in 50-75% of patients in both groups (except for diplopia, occurring only with LTG). Concomitant AED plasma concentrations were not markedly changed by LTG. LTG pharmacokinetics were linear over the range of 500-700 mg/day. Conclusions: LTG doses ~7 0 0 mg/day can be tolerated in patients receiving concomitant enzyme-inducing AEDs.
John Wiley & Sons, Ltd eBooks, Nov 17, 2015
Neurology, Sep 1, 1992
Article abstract-An atypical form of herpes simplex encephalitis produced by HSV-1 documented in ... more Article abstract-An atypical form of herpes simplex encephalitis produced by HSV-1 documented in the present article demonstrates that (1) prominent EEG abnormality may correlate with subtle increase in signal intensity on MRI; (2) the disease may start with prominent involvement of the cingulate gyri; and (3) viral infection of the brainstem may cause early onset of severe neurologic dysfunction and coma.
Archives of neurology, Jul 1, 1979
Page 1. Safety Precautions With Spongiform Encephalopathy To the Editor.\p=m-\Thearticle of Cook ... more Page 1. Safety Precautions With Spongiform Encephalopathy To the Editor.\p=m-\Thearticle of Cook and Austin in the Archives (35:697\x=req-\ 698,1978) contains disturbing implica-tions, which may have far-reaching results that were obviously not the intention of the authors. ...
Blackwell Science, Inc. eBooks, Jan 14, 2008
Neurology, 2016
OBJECTIVE: Report a unique case of immunotherapy and anti-epileptic drug (AED)-resistant Glutamic... more OBJECTIVE: Report a unique case of immunotherapy and anti-epileptic drug (AED)-resistant Glutamic acid decarboxylase 65 (GAD65)-associated autoimmune epilepsy demonstrating improvement with exogenous testosterone replacement. BACKGROUND: Treatment response in autoimmune epilepsy is variable, often dependent on the specific neuronal antibody involved, with GAD65-associated epilepsy amongst the most challenging to treat. There have been reports of improvement in seizure frequency in non-autoimmune epilepsy following administration of testosterone; however, an association between sex steroids and autoimmune epilepsy has not been reported previously. DESIGN/METHODS: Case Report RESULTS: A 47-year-old Caucasian man with treatment refractory GAD65-associated autoimmune epilepsy (CSF and serum GAD65 titer >250 IU/mL) and primary hypogonadism was admitted for long-term video EEG monitoring to objectify the patient9s observation that the testosterone replacement prescribed by his primary ...
American Journal of EEG Technology, 1986
ABSTRACT.REM sleep can be easily identified in standard EEG montages by analysis of eye movements... more ABSTRACT.REM sleep can be easily identified in standard EEG montages by analysis of eye movements in sleep, and the method of visual analysis was described. The patient should be asked upon arousal whether or not dreaming has occurred. Identification of REM sleep is important, because it may indicate significant abnormality of the wake-sleep cycle. Overnight sleep deprivation alone may be sufficient to cause shortening of the REM latency. Common clinical features that were associated with REM sleep in standard EEGs, were reviewed. The hospital environment is particularly likely to interfere with the patients' wake-sleep cycle.
Electroencephalography and Clinical Neurophysiology, 1995
The Western journal of medicine, 1990
Journal of the Iowa Medical Society, 1976
Neurology, 1985
ABSTRACT We conducted a pilot study of fluzinamide in 15 adults with refractory partial seizures.... more ABSTRACT We conducted a pilot study of fluzinamide in 15 adults with refractory partial seizures. After a baseline period, fluzinamide was added to the existing regimen of phenytoin and carbamazepine and increased to maximum tolerated dose. Common side effects included dizziness, diplopia, ataxia, headache, nausea, and rash, resulting in patient withdrawal in six cases. Seizures became less frequent in four of the nine patients who completed the 8-week trial.
Archives of Neurology, 1982
The Treatment of Epilepsy
Neurology, Nov 1, 1993
We evaluated the efficacy and safety of lamotrigine (300 and 500 mg/day) as add-on therapy in a m... more We evaluated the efficacy and safety of lamotrigine (300 and 500 mg/day) as add-on therapy in a multicenter, randomized, double-blind, parallel-group, placebo-controlled study of 216 patients with refractory partial seizures. During 6 months of treatment, median seizure frequency decreased by 8% with placebo, 20% with 300 mg lamotrigine, and 36% with 500 mg lamotrigine. Seizure frequency decreased by ≥50% in one-third of the 500-mg group and one-fifth of the 300-mg group. Reductions in seizure frequency and seizure days were statistically significant, compared with placebo, for the 500-mg group but not the 300-mg group. Most adverse events were minor and resolved over time. Nine percent of patients on lamotrigine withdrew because of adverse experiences. Lamotrigine plasma concentrations appeared to be a linear function of dose, and the drug did not affect plasma concentrations of concomitant antiepileptic drugs. Lamotrigine was safe, effective, and well tolerated as add-on therapy for refractory partial seizures.
The New England Journal of Medicine, Jun 25, 1998
Background Acute repetitive seizures are readily recognizable episodes involving increased seizur... more Background Acute repetitive seizures are readily recognizable episodes involving increased seizure frequency. Urgent treatment is often required. Rectal diazepam gel is a promising therapy. Methods We conducted a randomized, doubleblind, parallel-group, placebo-controlled study of home-based treatment for acute repetitive seizures. Patients were randomly assigned to receive either rectal diazepam gel, at doses ranging from 0.2 to 0.5 mg per kilogram of body weight on the basis of age, or placebo. Children received one dose at the onset of acute repetitive seizures and a second dose four hours later. Adults received three doses-one dose at onset, and two more doses 4 and 12 hours after onset. Treatment was administered by a care giver, such as a parent, who had received special training. The number of seizures after the first dose was counted for 12 hours in children and for 24 hours in adults.
Epilepsy & Behavior, Feb 1, 2004
This open-label, 6-year continuation study of several short-term clinical trials was conducted to... more This open-label, 6-year continuation study of several short-term clinical trials was conducted to assess the long-term tolerability and efficacy of lamotrigine when used as adjunctive therapy or monotherapy for partial seizures in adult patients (P 16 years) with epilepsy. Study visits occurred every 24 weeks throughout the treatment period. Of the 527 patients enrolled in the long-term continuation study, 508 were exposed to lamotrigine for at least 6 months (including their exposure in the primary clinical study), and 248 were exposed to lamotrigine for at least 5 years. Of the 527 patients, 75 received initial lamotrigine exposure during this study. Investigators judged that overall clinical status at the end of the study or at time of discontinuation (whichever occurred first) was improved moderately or markedly relative to prelamotrigine clinical status for 36% of patients. The most common treatment-emergent adverse events (regardless of suspected cause) were dizziness, diplopia, and headache. The only serious treatment-emergent adverse event occurring at a frequency exceeding 2% was accidental injury (2.7% of patients). Adverse events prompted 28 patients to discontinue from the study. The most common adverse events leading to discontinuation were dizziness (1.3%), headache (0.8%), rash (0.8%), and somnolence (0.6%). All adverse events resolved without sequelae. Lamotrigine administered as monotherapy or adjunctive therapy during a 6-year open-label continuation study was associated with a low incidence of adverse events in adult patients with epilepsy.
Electroencephalography and Clinical Neurophysiology, May 1, 1975
Electroencephalography and Clinical Neurophysiology, Nov 27, 1976
Neurosurgery, Feb 1, 1986
Neurosurgery, Feb 1, 1986
This case report describes a 29-year-old man with subarachnoid hemorrhage due to an anterior spin... more This case report describes a 29-year-old man with subarachnoid hemorrhage due to an anterior spinal artery aneurysm. Surgical obliteration of the aneurysm was successful. This is the sixth reported case of an isolated symptomatic aneurysm of a spinal artery.
Epilepsia, Sep 1, 1996
This study was undertaken to evaluate the dose tolerability and safety of a chronic ascending twi... more This study was undertaken to evaluate the dose tolerability and safety of a chronic ascending twice-daily (b.i.d.) dosage regimen of G700 mg/day larnotrigine (LTG) and to include determination of the LTG pharmacokinetic profile at doses 2500 mg/day in patients receiving concomitant enzyme-inducing antiepileptic drugs (AEDs). Methods: Twelve adult male epileptic patients treated with enzyme-inducing AEDs received S700 mg/day (b.i.d.) oral LTG (n = 8) or placebo (controls, n = 4). For 3 weeks, as outpatients they had their LTG dosage increased from 100 to 400 mg/day. Then, in a clinical research study unit, patients received regimens of 500, 600, and 700 mg/day for 1 week each. Controls received matching placebo in the same sequence. At study end, dosages were tapered in 2 weeks. Follow-up evaluations were made 7 days later. Results: Five LTG patients tolerated 700 mg/day for 1 week. LTG was reduced to 600 mglday in a patient with mild diplopia and to 500 mg/day in a patient with mild oscillopsia and diplopia. One patient discontinued 300mg/day therapy with a moderately intense diffuse papular skin rash, attributed to LTG. Headache, drowsiness, faintness, and diplopia, the common adverse events (AEs), were mild to moderate in intensity and occurred in 50-75% of patients in both groups (except for diplopia, occurring only with LTG). Concomitant AED plasma concentrations were not markedly changed by LTG. LTG pharmacokinetics were linear over the range of 500-700 mg/day. Conclusions: LTG doses ~7 0 0 mg/day can be tolerated in patients receiving concomitant enzyme-inducing AEDs.